Skip to main content

Table 2 Treatment-emergent adverse events occurring in NPC patients during the study in the safety analysis set

From: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Adverse event Famitinib alone Famitinib with CCRT
Grade 1–2 Grade 3 Grade 4 Grade 5 Total Grade 1–2 Grade 3 Grade 4 Grade 5 Total
Leukopenia 1 (5%) 0 0 0 1 (5%) 2 (10%) 17 (85%) 1 (5%) 0 20 (100%)
Neutropenia 1 (5%) 0 0 0 1 (5%) 9 (45%) 10 (50%) 1 (5%) 0 20 (100%)
Anaemia 2 (10%) 0 0 0 2 (10%) 16 (80%) 4 (20%) 0 0 20 (100%)
Radiation mucositis 0 0 0 0 0 16 (80%) 3 (15%) 1 (5%) 0 20 (100%)
Nausea and vomiting 0 0 0 0 0 16 (80%) 1 (5%) 0 0 17 (85%)
Radiation dermatitis 0 0 0 0 0 13 (65%) 0 0 0 13 (65%)
Weight loss 0 0 0 0 0 15 (75%) 0 0 0 15 (75%)
Proteinuria 1 (5%) 0 0 0 1 (5%) 15 (75%) 1 (5%) 0 0 16 (80%)
Thrombopenia 0 0 0 0 0 10 (50%) 3 (15%) 1 (5%) 0 14 (70%)
Hypertension 3 (15%) 0 0 0 3 (15%) 8 (40%) 1 (5%) 0 0 9 (45%)
Liver function impairment 3 (15%) 0 0 0 3 (15%) 10 (50%) 1 (5%) 0 0 11 (55%)
Hypertriglyceridemia 5 (25%) 0 0 0 5 (25%) 5 (25%) 0 0 0 5 (25%)
Hearing impairment 0 0 0 0 0 4 (20%) 0 0 0 4 (20%)
Renal impairment 0 0 0 0 0 4 (20%) 0 0 0 4 (20%)
Hematuria 2 (10%) 1 (5%) 0 0 3 (15%) 4 (20%) 1 (5%) 0 0 5 (25%)
Haemorrhage 0 0 0 0 0 2 (10%) 0 0 0 2 (10%)
Skin rash 2 (10%) 0 0 0 2 (10%) 1 (5%) 0 0 0 1 (5%)
Hypothyroidism 0 0 0 0 0 0 0 0 0 0
Hypercholesterolemia 1 (5%) 0 0 0 1 (5%) 0 0 0 0 0
Elevated total bilirubin 1 (5%) 0 0 0 1 (5%) 1 (5%) 0 0 0 1 (5%)
Elevated GGT 2 (10%) 0 0 0 2 (10%) 2 (10%) 0 0 0 2 (10%)
  1. CCRT concurrent chemoradiotherapy, GGT gamma glutamyl transpeptidase, NPC nasopharyngeal carcinoma
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us